Ipilimumab-associated colitis: CT findings

American Journal of Roentgenology

Volumn 200, Issue 5, 2013, Pages

  Kim, Kyung Won ^a,b   Ramaiya, Nikhil H ^a   Krajewski, Katherine M ^a   Shinagare, Atul B ^a   Howard, Stephanie A ^a   Jagannathan, Jyothi P ^a   Ibrahim, Nageatte ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b University of Ulsan College of Medicine   (South Korea)

Author keywords

Colitis; CT; Diverticulosis; Ipilimumab; Segmental colitis

Indexed keywords

ANTIBIOTIC AGENT; DIATRIZOATE; IOPROMIDE; IPILIMUMAB; MEGLUMINE DIATRIZOATE; STEROID; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; BOWEL MUCOSAL ENHANCEMENT; BOWEL WALL THICKENING; CLINICAL ARTICLE; CLINICAL FEATURE; COLITIS; COMPUTED TOMOGRAPHY SCANNER; CONTROLLED STUDY; DIARRHEA; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DIVERTICULOSIS; FEMALE; HUMAN; IMAGE ANALYSIS; INTESTINE DISTENSION; MALE; MEDICAL RECORD REVIEW; MESENTERIC VESSEL ENGORGEMENT; MESENTERY BLOOD VESSEL; MULTIDETECTOR COMPUTED TOMOGRAPHY; MULTIPLE CYCLE TREATMENT; MUSCLE CRAMP; NUCLEAR MAGNETIC RESONANCE SCANNER; PERICOLIC FAT STRANDING; PNEUMATOSIS INTESTINALIS; PRIORITY JOURNAL; RADIOLOGICAL PARAMETERS; RETROSPECTIVE STUDY; CHEMICALLY INDUCED DISORDER; COMPUTER ASSISTED TOMOGRAPHY; METHODOLOGY; MIDDLE AGED; RADIOGRAPHY; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; COLITIS; FEMALE; HUMANS; MALE; MIDDLE AGED; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED;

MLCS; MLOWN;

EID: 84879292862     PISSN: 0361803X     EISSN: 15463141     Source Type: Journal    
DOI: 10.2214/AJR.12.9751     Document Type: Article

References (24)

1. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-723
2. Hoos A, Ibrahim R, Korman A, et al. Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy. Semin Oncol 2010; 37:533-546
3. O'Regan KN, Jagannathan JP, Ramaiya N, Hodi FS. Radiologic aspects of immune-related tumor response criteria and patterns of immune-related adverse events in patients undergoing ipilimumab therapy. AJR 2011; 197:W241-W246
4. Weber JS, Kahler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 2012; 30:2691-2697
5. Di Giacomo AM, Biagioli M, Maio M. The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications. Semin Oncol 2010; 37:499-507
6. Prasad Shanbhogue AK, Prasad SR, Jagirdar J, et al. Comprehensive update on select immune-mediated gastroenterocolitis syndromes: implications for diagnosis and management. Radio-Graphics 2010; 30:1465-1487
7. Berman D, Parker SM, Siegel J, et al. Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma. Cancer Immun 2010; 10:11
8. Lyall A, Vargas HA, Carvajal RD, Ulaner G. Ipilimumab-induced colitis on FDG PET/CT. Clin Nucl Med 2012; 37:629-630
9. Bronstein Y, Ng CS, Hwu P, Hwu WJ. Radiologic manifestations of immune-related adverse events in patients with metastatic melanoma undergoing anti-CTLA-4 antibody therapy. AJR 2011; 197:W992-W1000
10. Bharucha AE, Tremaine WJ, Johnson CD, Batts KP. Ischemic proctosigmoiditis. Am J Gastroenterol 1996; 91:2305-2309
11. Thoeni RF, Cello JP. CT imaging of colitis. Radiology 2006; 240:623-638
12. Macari M, Balthazar EJ. CT of bowel wall thickening: significance and pitfalls of interpretation. AJR 2001; 176:1105-1116
13. Latella G, Vernia P, Viscido A, et al. GI distension in severe ulcerative colitis. Am J Gastroenterol 2002; 97:1169-1175
14. Kirkpatrick ID, Greenberg HM. Gastrointestinal complications in the neutropenic patient: characterization and differentiation with abdominal CT. Radiology 2003; 226:668-674
15. Peppercorn MA. The overlap of inflammatory bowel disease and diverticular disease. J Clin Gastroenterol 2004; 38:S8-S10
16. Thompson JA, Hamid O, Minor D, et al. Ipilimumab in treatment-naive and previously treated patients with metastatic melanoma: retrospective analysis of efficacy and safety data from a phase II trial. J Immunother 2012; 35:73-77
17. Kaehler KC, Piel S, Livingstone E, Schilling B, Hauschild A, Schadendorf D. Update on immunologic therapy with anti-CTLA-4 antibodies in melanoma: identification of clinical and biological response patterns, immune-related adverse events, and their management. Semin Oncol 2010; 37: 485-498
18. Beck KE, Blansfield JA, Tran KQ, et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol 2006; 24:2283-2289
19. Yang JC, Hughes M, Kammula U, et al. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother 2007; 30:825-830
20. Sultan K, Fields S, Panagopoulos G, Korelitz BI. The nature of inflammatory bowel disease in patients with coexistent colonic diverticulosis. J Clin Gastroenterol 2006; 40:317-321
21. Freeman HJ. Natural history and long-term clinical behavior of segmental colitis associated with diverticulosis (SCAD syndrome). Dig Dis Sci 2008; 53:2452-2457
22. Koutroubakis IE, Antoniou P, Tzardi M, Kouroumalis EA. The spectrum of segmental colitis associated with diverticulosis. Int J Colorectal Dis 2005; 20:28-32
23. Thornton E, Howard SA, Jagannathan J, et al. Imaging features of bowel toxicities in the setting of molecular targeted therapies in cancer patients. Br J Radiol 2012; 85:1420-1426
24. Freeman HJ. Colitis associated with biological agents. World J Gastroenterol 2012; 18:1871-1874